Further to your conjecture on 1.5 v 2 mg studies. My understanding is effect size is close in aggregate BUT 2 mg is better for primary end points on pain and function. Read SW comments on confidence in achieving strong data set to allow PAR to monetise before read out. SW has chosen his words carefully and NOT given away too much here
Further to your conjecture on 1.5 v 2 mg studies. My...
-
- There are more pages in this discussion • 331 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 29.5¢ | $89.62K | 294.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20607 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 16773 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |